anlotinib + capecitabine + toripalimab

This triplet combination therapy consists of anlotinib, a multi-target tyrosine kinase inhibitor; capecitabine, a cytotoxic fluoropyrimidine carbamate; and toripalimab, a humanized monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor. Anlotinib exerts its effects by inhibiting tumor angiogenesis and growth through the blockade of VEGFR, FGFR, PDGFR, and c-Kit signaling pathways. Capecitabine acts as an oral prodrug of 5-fluorouracil, functioning as an antimetabolite that interferes with DNA synthesis by inhibiting thymidylate synthase. Toripalimab enhances the immune system's ability to detect and destroy cancer cells by preventing the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The combination is primarily being investigated by the Affiliated Hospital of North Sichuan Medical College for the treatment of triple-negative breast cancer (TNBC), aiming to leverage the synergistic potential of anti-angiogenesis, chemotherapy, and immune checkpoint inhibition.

Brand names

FukanghuaTuoyi

Other names

Anlotinib hydrochlorideJS-001JS001JS 001TAB001TAB-001TAB 001